PHF6 mutations in paediatric acute myeloid leukaemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10332741" target="_blank" >RIV/00064203:_____/16:10332741 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10332741
Result on the web
<a href="http://dx.doi.org/10.1111/bjh.13891" target="_blank" >http://dx.doi.org/10.1111/bjh.13891</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.13891" target="_blank" >10.1111/bjh.13891</a>

Result language
angličtina
Original language name
PHF6 mutations in paediatric acute myeloid leukaemia
Original language description
Paediatric acute myeloid leukaemia (AML) is a heterogeneous disease characterized by the presence of different collaborating cytogenetic aberrations that are associated with outcome (Pui et al, 2011; Creutzig et al, 2012). New prognostically relevant genetic aberrations have recently been identified, such as mutations in NPM1 and FLT3, which further improve risk-group stratification, but the underlying genetic abnormalities are not fully understood in approximately 20% of paediatric AML cases (Pui et al, 2011; Creutzig et al, 2012). Unravelling the underlying aberrations involved in leukaemogenesis may improve risk-group stratification.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)